A novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients
Antimicrobial Agents and Chemotherapy · 01.07.2026 · 70 (7)
DOI: 10.1128/aac.00372-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 01.07.2026. Verfasst von Caroline Briquet und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cliniques Universitaires Saint-Luc, Antimicrobial Stewardship, Brussels, Belgium. Hauptthemen laut MEDLINE: Meropenem, Anti-Bacterial Agents, Thienamycins. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds De La Recherche Scientifique - FNRS, CuSL Antimicrobial Management Team (AMT).
Abstract (Originalsprache)
Meropenem is a valuable option for outpatient parenteral antimicrobial therapy (OPAT) due to its broad-spectrum activity, including multidrug-resistant Gram-negative bacteria, particularly when no oral alternatives exist. However, its conventional thrice-daily dosing poses logistical challenges for home administration, as the third dose typically falls during nighttime. This prospective pharmacokinetic study evaluated the adequacy of a novel daytime-only meropenem regimen adapted for OPAT in non-critically ill hospitalized patients. Twenty-two patients receiving meropenem 2 g every 8 h were switched, once clinically stable, to a thrice-daily, 6-hourly regimen compatible with daytime administration only. Meropenem was infused over 20 min. At steady state, unbound meropenem concentrations were measured for both regimens. These data informed a population pharmacokinetic model and Monte Carlo simulations to compare the probability of achieving predefined PK/PD targets. Both the conventional and OPAT-adapted regimens achieved a probability of target attainment (PTA) >90% for 40% f T >MIC at MIC ≤4 mg/L, exceeding the EUCAST/IDSA susceptibility breakpoint of 2 mg/L. Extending the infusion duration to 3 or 5 h with the OPAT-adapted schedule restored PTA >90% for MIC ≤8 mg/L. However, trough concentrations after the evening dose were lower with the OPAT-adapted regimen than with the standard regimen (1–2 vs 3–5 mg/L, depending on infusion duration). This may increase the risk of resistance selection despite the post-antibiotic effect of meropenem. With this caveat, OPAT regimens, with infusion duration adapted to MIC, may enable practical daytime-only meropenem administration, avoiding the need for overnight nursing visits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cliniques Universitaires Saint-Luc, Antimicrobial Stewardship, Brussels, Belgium.
- Department of Pharmacy, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- UCLouvain, Louvain Drug Research Institute, Pharmacologie Cellulaire et Moléculaire, Brussels, Belgium.
- Clinical Microbiology Department, Cliniques Universitaires Saint-Luc, Brussels, Belgium.
- Faculty of Health Medicine and Behavoural Science, The University of Queensland, University of Queensland Centre for Clinical Research, Brisbane, Australia.
- Laboratory of Clinical Microbiology, KU Leuven, Leuven, Belgium.
ORCID-Profile: Caroline Briquet, Perrin Ngougni Pokem, Xin Liu, Gert-Jan Wijnant, Olivier Cornu, Halil Yildiz, Alexia Verroken, Jean Cyr Yombi, Françoise Van Bambeke
Förderung
- Fonds De La Recherche Scientifique - FNRS
- CuSL Antimicrobial Management Team (AMT)
Zitieren
APA
Briquet, C., Ngougni Pokem, P., Liu, X., Wijnant, G. J., Cornu, O., Yildiz, H., Verroken, A., Roberts, J. A., Yombi, J. C., & Van Bambeke, F. (2026). A novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients. Antimicrobial Agents and Chemotherapy, 70(7). https://doi.org/10.1128/aac.00372-26
Vancouver
Briquet C, Ngougni Pokem P, Liu X, Wijnant GJ, Cornu O, Yildiz H, et al. A novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients. Antimicrobial Agents and Chemotherapy. 2026;70(7). doi:10.1128/aac.00372-26
BibTeX
@article{Briquet2026,
author = {Briquet, Caroline and Ngougni Pokem, Perrin and Liu, Xin and Wijnant, Gert-Jan and Cornu, Olivier and Yildiz, Halil and Verroken, Alexia and Roberts, Jason A and Yombi, Jean Cyr and Van Bambeke, Françoise},
title = {A novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {7},
doi = {10.1128/aac.00372-26}
}
EUVIMED